Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Severe Hypertriglyceridemia Clear all

Conditions: Hypertriglyceridemia
Interventions: ISIS apoC-III Rx, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Farmville, North Carolina • Greenville, North Carolina • Kinston, North Carolina + 1 more

Conditions: Severe Hypertriglyceridemia
Interventions: ARO-APOC3, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 33
States / cities: Beverly Hills, California • Palm Springs, California • Boca Raton, Florida + 26 more

Conditions: Severe Hypertriglyceridemia
Interventions: AKR-963; Drug
Lead sponsor: Trygg Pharma, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Severe Hypertriglyceridemia, Mixed Dyslipidaemia
Interventions: Gemcabene, Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 48
States / cities: Fort Payne, Alabama • Tucson, Arizona • Beverly Hills, California + 41 more

Conditions: Lipodystrophy (Genetic or Acquired, Non HIV)
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2034
U.S. locations: 2
States / cities: Bethesda, Maryland • Ann Arbor, Michigan

Conditions: Severe Hypertriglyceridemia
Interventions: Pegozafermin, Placebo; Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 73
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 65 more

Conditions: Hypertriglyceridemia
Interventions: Epanova, Olive Oil; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Los Angeles, California • St. Petersburg, Florida • Addison, Illinois + 11 more

Conditions: Severe Hypertriglyceridemia
Interventions: K-877, Fenofibrate, Placebo (for K-877), Placebo (for Fenofibrate); Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 110
States / cities: Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 94 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia
Interventions: Metformin Eicosapentaenoate, Metformin HCl and Vascepa; Drug
Lead sponsor: Thetis Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hypertriglyceridemia, Severe Hypertriglyceridemia
Interventions: ION775; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Lincoln, California • Aurora, Colorado • Boca Raton, Florida + 13 more

Conditions: Severe Hypertriglyceridemia
Interventions: Epanova, Lovaza; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Kansas City, Kansas • Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: Generalized Lipodystrophy
Interventions: mibavademab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Bethesda, Maryland • Ann Arbor, Michigan

Conditions: Hypertriglyceridemia
Interventions: CaPre, Placebo; Drug
Lead sponsor: Grace Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 69
States / cities: Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 57 more

Conditions: Non Familial Chylocmicronemia Syndrome (Non-FCS)
Interventions: LCQ908, Fenofibrate, Fish Oil, Placebo of LCQ908, Placebo of fenofibrate, Placebo of fish oil; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 28
States / cities: Muscle Shoals, Alabama • Glendale, Arizona • Encinitas, California + 23 more

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 52
States / cities: Garden Grove, California • Lake Forest, California • Montclair, California + 42 more

Conditions: Severe Hypertriglyceridemia
Interventions: Olezarsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 65
States / cities: Los Angeles, California • San Diego, California • Tarzana, California + 53 more

Conditions: Hypertriglyceridemia
Interventions: evinacumab, Placebo; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 32
States / cities: Newport Beach, California • New Haven, Connecticut • Boca Raton, Florida + 26 more

Conditions: Hyperlipidemias, Hypertriglyceridemia, Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases
Interventions: CAT-2003, Placebo; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Miami, Florida • Indianapolis, Indiana • Auburn, Maine + 1 more

Conditions: Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 21
States / cities: Lincoln, California • Montclair, California • Boca Raton, Florida + 17 more

Conditions: Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)
Interventions: Plozasiran; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 15 Years and older
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Hypertriglyceridemia
Interventions: ARI-3037MO, Placebo; Drug
Lead sponsor: Arisaph Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Tustin, California • Louisville, Kentucky • Auburn, Maine + 2 more

Conditions: Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG), Mixed Hyperlipemia, Hypercholesterolaemia
Interventions: CTX310; Drug
Lead sponsor: CRISPR Therapeutics AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: Hialeah, Florida • Jacksonville, Florida • Orlando, Florida + 5 more

Conditions: Severe Hypertriglyceridemia
Interventions: K-877, Fenofibrate, Placebo (for K-877); Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 129
States / cities: Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more

Conditions: Severe Hypertriglyceridemia
Interventions: Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

A Study to Assess the Safety, Tolerability and Efficacy of ION775

An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation